Key Drivers
- Strong Profitability
- Healthy Liquidity
- Elevated Valuation
AIAI Summary
ARQT has transitioned into a profitable, cash-generating commercial biotech driven by ZORYVE's rapid growth and 92% gross margins, but its premium valuation makes sustained prescription growth, payer access, and cash conversion essential given heavy single-franchise concentration.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Profitability
- •Healthy Liquidity
- •Elevated Valuation
ARQT's profitability, cash flow, and liquidity improved sharply, but elevated working capital, leverage, stock compensation, and an expensive valuation warrant caution.
Price Behavior
Key Price Behavior Insights:
- •Volatile recovery
- •Rising average
- •Key resistance
ARQT was volatile but mildly constructive last month, with support at $23.40–$23.90 and a breakout above $26.50 needed to confirm further upside.
Sharp decline and rebound mid-period highlighted elevated volatility
Sentiment & News
Key News Insights:
- •Raised guidance
- •Zoryve momentum
- •Institutional buying
Arcutis' raised guidance, Zoryve momentum, and institutional buying support a positive outlook despite near-term earnings-estimate risk.
The developments are broadly bullish for Arcutis shares, though valuation sensitivity to estimates may drive volatility
Similar Companies in Healthcare
Other companies in the same sector with AI ratings